List view / Grid view
23 May 2019 | By Sartorius
Join us as we discuss the promises and pitfalls associated with developing individualised antigen-specific T-cell therapy products for clinical use.
Researchers have shown how skin vaccinations could be used as a vaccination strategy for sexually transmitted infections (STIs).
Comprehensive tumour profiling promises new therapeutic options for patients with advanced cancer.
A method to view the immune cell 'landscape' of bowel cancer tumours could pave the way towards more individualised medicine and treatment...
Rapid drug response screening for leukaemia stem cells offers clues to relapse and to improving patient-specific therapies...
Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...
A novel hybrid approach has revealed a 3D structure of a protein fragment that could serve as a drug target in treating stroke patients...
Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers...
A research team has developed a nano-platform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma...
14 August 2018 | By Bio-Techne
With recent advances in medicine, cellular therapies are one step closer to becoming a reality where re-programmed cells, tissues and organs can be used as therapeutic agents. This webinar discussed the journey of medical treatments from small molecule to cellular therapies...
Since beta cells and neurological tissues have common receptors, researchers screened brain radioligands for their ability to identify beta cells...
Researchers use data science and genomics to help determine best treatment options for specific bladder cancers...
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
